NTHI
NeOnc Technologies Holdings, Inc.9.44
-0.44-4.45%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
183.84MP/E (TTM)
-Basic EPS (TTM)
-2.51Dividend Yield
0%Recent Filings
8-K
Third $1M stock offering launched
NeOnc Technologies Holdings entered a third Securities Purchase Agreement on March 20, 2026, to sell up to 545,583 shares at $7.20 each and five-year warrants exercisable at $9.00. Initial closing issued 138,889 shares and warrants to one investor for $1 million; offering runs through April 30. Funds fuel working capital. Resale registration follows 10-K filing.
8-K
NeOnc names Choi CAO
NeOnc Technologies appointed David Choi as Chief Accounting Officer effective March 12, 2026, to oversee accounting, financial reporting, internal controls, and governance amid clinical expansion. Choi, a CPA with over a decade at Blythe Global Advisors, Grant Thornton, and EY, signed on with $162,500 base salary and 170,000 restricted shares—53,333 vested immediately, 58,333 at one-year, balance performance-tied. Bolsters public company compliance. No interim gaps disclosed.
8-K
NEO212 Phase 1 sets RP2D
NeOnc Technologies announced Phase 1 dose-escalation results for oral NEO212 on March 4, 2026, hitting maximum tolerated dose at 810 mg (Cohort 5) after a second DLT, halting escalation, and setting RP2D at 610 mg (Cohort 4) for Phase 2a. No clinically meaningful myelosuppression or organ toxicity emerged, unlike TMZ. Early anti-tumor activity shone in recurrent GBM and brain mets. RP2D locked in.
8-K
Settles Fox Infused dispute
8-K
NeOnc closes $1.45M placement
NeOnc Technologies closed a $1.45 million private placement on February 25, 2026, issuing 201,390 shares at $7.20 each and five-year warrants exercisable at $9.00 to four investors. This follows January closings raising $10.6 million under prior agreements, with net proceeds earmarked for working capital. Warrants boost potential dilution. Resale registration follows 10-K filing.
BIVI
BioVie Inc.
1.43+0.00
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
BZYR
Burzynski Research Institute, I
0.03-0.00
INTS
Intensity Therapeutics, Inc.
0.44+0.02
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
NBTX
Nanobiotix S.A.
22.32+0.18
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
RNXT
RenovoRx, Inc.
0.84-0.10